LDE225 + INC424
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis
Conditions
Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera, Myeloproliferative Disorders, Bone Marrow Diseases, Hematologic Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, Hemorrhagic Disorders
Trial Timeline
May 8, 2013 → Apr 10, 2018
NCT ID
NCT01787552About LDE225 + INC424
LDE225 + INC424 is a phase 1/2 stage product being developed by Novartis for Primary Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01787552. Target conditions include Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01787552 | Phase 1/2 | Completed |
Competing Products
20 competing products in Primary Myelofibrosis